Tarlatamab treatment

Phase 2Small molecule

JJonsson Comprehensive Cancer Center

Tarlatamab treatment is one of 2 small molecule programs targeting Diagnosis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

DiagnosisNot yet recruiting

DLL3-Expressing TumorsActive, not recruiting

DiagnosisPhase 2

Not yet recruiting

DLL3-Expressing TumorsPhase 2

Active, not recruiting

Competition

Competitive Landscape

1 competitor in Diagnosis

#DrugCompanyPhaseTrials

Tarlatamab treatment

JJonsson Comprehensive Cancer Center

Phase 2

1 2

Blood Taking

CCentre Hospitalier Universitaire de Besancon

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2029

Phase 2Active, not recruiting

DLL3-Expressing Tumors

NCT06788938

Q3 2030

Phase 2Not yet recruiting

Diagnosis

NCT07788365

Clinical

Trials by Indication[1]

DLL3-expressing Tumors1 trial

Tarlatamab in Advanced DLL3-Expressing Tumors Including Neuroendocrine Neoplasms

Active, not recruiting·JJonsson Comprehensive Cancer Center·Phase 2·NCT06788938·29 enrolled

Diagnosis1 trial

Tarlatamab in Recurrent Gynecological Neuroendocrine Carcinomas: A Phase II Proof-of-concept Study

Not yet recruiting·UUniversity Hospital, Strasbourg, France·Phase 2·NCT07788365·20 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Tarlatamab treatment. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Tarlatamab treatment compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Tarlatamab treatment. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Jonsson Comprehensive Cancer Center company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: JJonsson Comprehensive Cancer Center

Tarlatamab treatment

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2029

Q3 2030

Trials by Indication[1]

DLL3-expressing Tumors1 trial

Diagnosis1 trial

References

Drug Info

Quick Facts

Related News